Galapagos, Adaptimmune to collaborate on Adaptimmune’s TCR T-cell therapy candidate

 

• Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancer
• Uza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date in a Phase 1 trial using Adaptimmune’s centralized manufacturing platform
• Initial in vitro testing of uza-cel produced on Galapagos' decentralized manufacturing platform has shown encouraging data that support further clinical development
• Adaptimmune to receive initial payments of $100 million, comprising $70 million upfront and $30 million of R&D funding, option exercise fees of up to $100 million, additional development and sales milestone payments of up to a maximum of $465 million, plus tiered royalties on net sales
• Galapagos has been granted an option to exclusively license uza-cel for global development and commercialization in head & neck cancer, and potential future solid tumor cancer indications

https://www.globenewswire.com/news-release/2024/05/30/2891111/0/en/Galapagos-and-Adaptimmune-sign-clinical-collaboration-agreement-with-an-option-to-exclusively-license-Adaptimmune-s-TCR-T-cell-therapy-candidate-uza-cel-in-head-neck-cancer-and-pot.html